News
Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color.
Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors.
That included Regeneron's prior drug discoveries that spanned from "treatments to prevent blindness, for allergic diseases from asthma to atopic dermatitis, for several forms of cancer, and even ...
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response by Vandana Singh Benzinga Editor Follow ...
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis Published on June 15, 2025 at 5:38 am by Maham Fatima in News ...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more ...
On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe ...
Sanofi and Regeneron have shared positive results from a phase 4 study of their monoclonal antibody Dupixent (dupilumab) in atopic dermatitis patients with skin of colour. Data from the open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results